Darbepoetin alfa and ferric gluconate ameliorate the anemia associated with recessive dystrophic epidermolysis bullosa

Pediatric Dermatology

Volumn 23, Issue 6, 2006, Pages 580-585

  Kuo, Dennis J ^a   Bruckner, Anna L ^a   Jeng, Michael R ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Pediatric Hematology/Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; FERRIC GLUCONATE; HEMOGLOBIN; IRON; IRON DEXTRAN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ADOLESCENT; ANEMIA; ARTICLE; BULLOUS SKIN DISEASE; CASE REPORT; CHILD; DISEASE ASSOCIATION; EPIDERMOLYSIS BULLOSA DYSTROPHICA; FEMALE; GENODERMATOSIS; HEMOGLOBIN DETERMINATION; HUMAN; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADOLESCENT; ANEMIA; CHILD; EPIDERMOLYSIS BULLOSA DYSTROPHICA; ERYTHROPOIETIN; FEMALE; FERRIC COMPOUNDS; GENES, RECESSIVE; HEMATINICS; HUMANS; MALE; RETROSPECTIVE STUDIES;

EID: 33751297012     PISSN: 07368046     EISSN: 15251470     Source Type: Journal    
DOI: 10.1111/j.1525-1470.2006.00314.x     Document Type: Article

References (18)

1. Fine JD, Johnson L, Suchindran C et al. The epidemiology of inherited epidermolysis bullosa. In: Fine JD, Bauer E, McGuire J, Moshell A, eds. Epidermolysis bullosa: clinical, epidemiologic, and laboratory advances and the findings of the National Epidermolysis Bullosa Registry. Baltimore, MD: The Johns Hopkins University Press, 1999:101-103.
2. Fine JD, Johnson LB, Weiner M et al. Chemoprevention of squamous cell carcinoma in recessive dystrophic epidermolysis bullosa: results of a phase 1 trial of systemic isotretinoin. J Am Acad Dermatol 2004;50:563-571.
3. Gasche C, Lomer MC, Cavill I et al. Iron, anaemia, and inflammatory bowel diseases. Gut 2004;53:1190-1197.
4. Birge K. Nutrition management of patients with epidermolysis bullosa. J Am Diet Assoc 1995;95:575-579.
5. Goodnough LT, Nissenson AR. Anemia and its clinical consequences in patients with chronic diseases. Am J Med 2004;116(Suppl. 7A):1S-2S.
6. Fridge JL, Vichinsky EP. Correction of the anemia of epidermolysis bullosa with intravenous iron and erythropoietin. J Pediatr 1998;132:871-873.
7. Smith R. Applications of darbepoietin-alpha, a novel erythropoiesis- stimulating protein, in oncology. Curr Opin Hematol 2002;9:228-233.
8. Faich G, Strobos J. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans. Am J Kidney Dis 1999;33:464-470.
9. Teucher B, Olivares M, Cori H. Enhancers of iron absorption: ascorbic acid and other organic acids. Int J Vitam Nutr Res 2004;74:403-419.
10. Antunes I, Resende C, Granjo E et al. Recombinant human erythropoietin alpha in the correction of anaemia in epidermolysis bullosa. J Eur Acad Dermatol Venereol 1999;12:181-182.
11. Atherton DJ, Cox I, Hann I. Intravenous iron (III) hydroxide-sucrose complex for anaemia in epidermolysis bullosa. Br J Dermatol 1999;140:773.
12. Fleming T. Red Book: pharmacy's fundamental reference. Montvale: Thomason Healthcare, 2005.
13. Hininger I, Waters R, Osman M et al. Acute prooxidant effects of vitamin C in EDTA chelation therapy and long-term antioxidant benefits of therapy. Free Radic Biol Med 2005;38:1565-1570.
14. Esposito BP, Breuer W, Sirankapracha P et al. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 2003;102:2670-2677.
15. Fine JD, Johnson LB, Weiner M et al. Assessment of mobility, activities and pain in different subtypes of epidermolysis bullosa. Clin Exp Dermatol 2004;29:122-127.
16. Reyes ML, Cattani A, Gajardo H et al. Bone metabolism in children with epidermolysis bullosa. J Pediatr 2002;140:467-469.
17. Fine JD, Johnson LB, Weiner M et al. Impact of inherited epidermolysis bullosa on parental interpersonal relationships, marital status and family size. Br J Dermatol 2005;152:1009-1014.
18. Horn HM, Tidman MJ. Quality of life in epidermolysis bullosa. Clin Exp Dermatol 2002;27:707-710.